Option chain shows key data for Incannex Healthcare's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Incannex Healthcare.

Incannex Healthcare (NASDAQ:IXHL) Stock, Option Chain

Incannex Healthcare

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

cannabis money (Hvoenok and GOR Photo on Shutterstock)(35)

Cannabis

Psychedelics

Financing

IXHL

Incannex Healthcare secures $60M in financing from Arena Investors to support clinical trials for cannabinoid and psychedelic therapies.

Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies

FDA approves Incannex&#39;s Phase 2 trial for psilocybin-assisted psychotherapy in treating generalized anxiety disorder, following a successful review of the IND application.

FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety

Cannabisl Regulation (Sora Shimazaki by Pexels)(3)

News

Health Care

Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for the treatment of opioid use disorder (OUD).A number of FDA representatives shared insights on the CannQuit-O development program during the pre-IND teleconference in addition to providing recommendations on the proposed clinical development strategy.

FDA Experts Weigh In On Incannex&#39;s CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder

Incannex Healthcare Inc

<p>Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) has outperformed the market over the past 15 years by 7.57% on an annualized basis producing an average annual return of 19.53%. Currently, Alphabet has a market capitalization of $2.40 trillion. </p>
<p><strong>Buying $1000 In GOOGL:</strong> If an investor had bought $1000 of GOOGL stock 15 years ago, it would be worth <strong>$14,265.60</strong> today based on a price of $195.86 for GOOGL at the time of writing.</p>
<h3>Alphabet's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737155709_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

GOOGL

Here's How Much You Would Have Made Owning Alphabet Stock In The Last 15 Years

<p>Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) has outperformed the market over the past 5 years by 37.92% on an annualized basis producing an average annual return of 50.45%. Currently, Broadcom has a market capitalization of $1.11 trillion. </p>
<p><strong>Buying $1000 In AVGO:</strong> If an investor had bought $1000 of AVGO stock 5 years ago, it would be worth <strong>$7,707.34</strong> today based on a price of $237.44 for AVGO at the time of writing.</p>
<h3>Broadcom's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737154808_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AVGO

$1000 Invested In Broadcom 5 Years Ago Would Be Worth This Much Today

<p><a href="https://www.benzinga.com/news/25/01/42947081/a-salary-is-the-drug-they-give-you-to-forget-your-dreams-says-kevin-oleary-encourages-people-to-embrace-the-fear-of-failure">Kevin O'Leary</a>, the investor famously known from Shark Tank, has once again stepped into the heated debate about TikTok's future in the United States. Alongside billionaire entrepreneur Frank McCourt, O'Leary is pushing a bold plan to save the platform from a potential nationwide ban, which he says would be devastating for small businesses nationwide.</p>
<h2 class="wp-block-heading">Why TikTok Matters to Small Businesses</h2>
<p>TikTok is a key tool for the success of many small businesses in America. Kevin O'Leary says six million businesses use the app to sell products, find customers and make money. If TikTok is shut down, it would cause big problems for these businesses.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
<li><strong><a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a></strong></li>
</ul>
<p>"I don&#8217;t want it shut down. It&#8217;s not good for my businesses, it&#8217;s not good for six million other small businesses in America that make a living off it," O'Leary said in a recent <a href="https://www.youtube.com/watch?v=9s94nz8JY-U">interview</a>. "We just need to take out the onerous piece – the spyware – that&#8217;s what Congress is upset about."</p>
<h2 class="wp-block-heading">The Spyware Problem</h2>
<p>TikTok&#8217;s controversy stems from its parent company, <a href="https://www.benzinga.com/tech/24/11/42069805/bytedance-valuation-soars-to-300b-despite-threat-of-us-tiktok-ban">ByteDance, a Chinese tech giant</a>. U.S. lawmakers from both parties have raised concerns about the app's data security and potential ties to the Chinese government. The fear is that TikTok's algorithm could serve as a tool for surveillance or propaganda.</p>
<p>O'Leary and McCourt's solution? Buy TikTok's U.S. operations outright. <a href="https://www.benzinga.com/general/entertainment/25/01/42834240/kevin-oleary-joins-the-peoples-bid-for-tiktok-as-pending-ban-looms">Their proposal</a> involves acquiring the app without its famous algorithm – the technology that powers TikTok's addictive "For You" feed. "We don&#8217;t want to buy the algorithm, we can&#8217;t use it. That&#8217;s spyware," O'Leary explained. "We&#8217;re going to rebuild the product and make it much better."</p>
<p><strong>See Also: With 100+ historic trademark victories, this company holds IP for some of the highest-grossing characters in history. Now, they've propelled these icons into the future using next-gen patented AR, VR, and AI technology. <a href="https://www.benzinga.com/money/elf-labs-1"><strong>There&#8217;s now a limited window for investors to claim shares at just $2/share with $980 minimum—but the clock is ticking.</strong></a></strong></p>
<h2 class="wp-block-heading">A Race Against Time</h2>
<p>The urgency behind O'Leary's bid is tied to a looming deadline. A law passed earlier this year could result in TikTok being banned in the United States starting Jan. 19, 2025, unless the app is sold. <a href="https://www.benzinga.com/general/social-media/24/12/42680367/tiktok-on-trial-supreme-court-prepares-to-weigh-national-security-risks">The Supreme Court is deciding</a> whether this law will go into effect and O'Leary and McCourt are pushing to get their offer accepted before it's too late.</p>
<p>Critics have questioned whether TikTok can remain popular without its algorithm, which is central to its success. The algorithm is the magic behind the content recommendations that keep users hooked. But O'Leary insists that the platform's success doesn't hinge on the existing technology.</p>
<p><strong>Trending: Built on the trusted network of Fortune 500 companies, <a href="https://www.benzinga.com/money/web3-enabler-the-most-boring-blockchain-company-partners-with-salesforce"><strong>this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100.</strong></a></strong></p>
<p>O'Leary and McCourt's group, called The People's Bid for TikTok, has support from investors and tech experts, including Tim Berners-Lee, the inventor of the World Wide Web. They've also talked to lawmakers and plan to work with President-elect Donald Trump to close the deal.</p>
<p>McCourt emphasized the importance of keeping TikTok running for its millions of users. "By keeping the platform alive without relying on the current TikTok algorithm and avoiding a ban, millions of Americans can continue to enjoy the platform," he said. "We look forward to working with ByteDance, President-elect Trump and the incoming administration to get this deal done."</p>
<p>Even though ByteDance has repeatedly stated that <a href="https://www.benzinga.com/general/social-media/25/01/42994923/mrbeast-discussing-buying-tiktok-with-billionaires-to-prevent-us-shutdown-lets-see-if-we-can-pull-this-off">TikTok is not for sale</a>, O&#8217;Leary and McCourt are committed to finding a solution.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</strong></a></strong></li>
<li><strong>According to Juniper Research, the total value of B2B cross-border payments stored on the blockchain is projected to exceed $4.4 trillion — <a href="https://www.benzinga.com/money/web3-enabler-future-of-enterprise-transactions"><strong>Join the first company to bring blockchain payments to Salesforce early with just $100.</strong></a></strong></li>
</ul>


Kevin O'Leary Warns That Shutting Down TikTok Would Hurt '6 Million Small Businesses In America' That Rely On It To Make A Living

<p>Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) has outperformed the market over the past 10 years by 7.04% on an annualized basis producing an average annual return of 18.27%. Currently, Live Nation Entertainment has a market capitalization of $31.27 billion. </p>
<p><strong>Buying $100 In LYV:</strong> If an investor had bought $100 of LYV stock 10 years ago, it would be worth <strong>$547.26</strong> today based on a price of $135.61 for LYV at the time of writing.</p>
<h3>Live Nation Entertainment's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737153016_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $100 Invested In Live Nation Entertainment 10 Years Ago Would Be Worth Today

Offerings

MOBX

Mobix Labs Files For Mixed Shelf Offering Of Up To $75M

Management

OKLO

Oklo's Christopher Wright Notified He Intended To Resign As A Director Upon His Confirmation As United States Secretary Of Energy

KULR

KULR Technology Group Files For Mixed Shelf Offering; Size Not Disclosed

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

Mawson Infrastructure Group Appoints William C. Regan As Chief Financial Officer

<p>On January&nbsp;13, 2025, Omega Therapeutics, Inc. (the "Company") received a notice of default (the "Notice of Default") under the Loan and Security Agreement, dated as of March&nbsp;9, 2018 (the "Loan Agreement"), by and between the Company and Banc of California ("BOC"), from BOC.</p>
<p>The Notice of Default specified that, in BOC's view, one or more events of default had occurred based on alleged material adverse changes in the Company's cash runway, financing opportunities, solvency, pre-clinical programs, stock price and corporate governance, pursuant to Sections 6.2, 8.3 and 8.5 of the Loan Agreement.</p>
<p>Based on its assertion of the alleged events of default, BOC declared all outstanding obligations under the Loan Agreement immediately due and payable purportedly in accordance with Section&nbsp;9.1(g) of the Loan Agreement. BOC also set off and applied to the balance of the Company's obligations under the Loan Agreement $14,666,666.72 of deposits of the Company held by BOC.</p>
<p>The Company has responded by letter to the Notice of Default, advising BOC that no events of default under the Loan Agreement have occurred or are continuing. Prior to receiving the Notice of Default, the Company had maintained the required minimum cash balances, and has timely paid BOC its indebtedness and other obligations as they become due. In addition, the bases for an event of default asserted in the Notice of Default, including with respect to the Company's stock price and corporate governance, do not align with the covenants in the Loan Agreement. The Company believes it is not in default under the Loan Agreement, and that BOC did not have the right to accelerate the indebtedness or otherwise pursue remedies thereunder, and has attempted to resolve this matter with BOC consensually, while reserving all of its rights to legal or regulatory action.</p>


Legal

OMGA

Omega Therapeutics Receives Default Notice From Banc Of California; Disputes Alleged Breach Of Loan Terms, Bank Sets Off $14.67M Deposits; Maintains Compliance Claims, Seeks Resolution

<p>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 10 years by 11.71% on an annualized basis producing an average annual return of 22.95%. Currently, Meta Platforms has a market capitalization of $1.55 trillion. </p>
<p><strong>Buying $100 In META:</strong> If an investor had bought $100 of META stock 10 years ago, it would be worth <strong>$798.50</strong> today based on a price of $612.36 for META at the time of writing.</p>
<h3>Meta Platforms's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737152107_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $100 Invested In Meta Platforms 10 Years Ago Would Be Worth Today

<p>On January 17, 2025, Tetra Tech EC, Inc. ("TtEC"), a wholly owned subsidiary of Tetra Tech, Inc. (the "Company"), entered into a settlement agreement with the United States of America, acting through the Civil Division of the United States Attorney's Office of the United States Department of Justice and on behalf of the Department of the Navy (collectively, the "United States"), and also filed a proposed consent decree with the United States District Court for the Northern District of California (the "Court"), to resolve the previously disclosed civil litigation related to TtEC's performance of environmental remediation services at the former Hunters Point Naval Shipyard in San Francisco, California (the "Covered Conduct").</p>
<p>&nbsp;</p>
<p>Under the terms of the settlement agreement and consent decree, TtEC has agreed to pay to the United States $57 million and $40 million for False Claims Act ("FCA") claims and Comprehensive Environmental Response, Compensation and Liability Act ("CERCLA") claims, respectively (the "Settlement Amounts"), which the Company expects to pay with cash on hand and by drawing on its credit facility. Upon entry of the Consent Decree by the Court and the United States' receipt of the settlement amounts, the United States will release TtEC from any and all civil or administrative monetary claims for the Covered Conduct under the civil FCA, the CERCLA, and other specified civil statutes and common law theories of liability.</p>
<p>&nbsp;</p>
<p>The consent decree is subject to a number of contingencies that could prevent it from being finalized with its current terms. In particular, and without limitation, (i) the consent decree is required to be lodged with the Court for a period of 30 days for public notice and comment, and the United States has reserved the right to withdraw or withhold its consent if the comments regarding the consent decree disclose facts or considerations that indicate the consent decree is inappropriate, improper or inadequate; and (ii) the Court might determine not to enter the consent decree as currently written or as approved by the United States. There can be no assurance that the contingencies will not preclude entry of the consent decree.</p>
<p>&nbsp;</p>
<p>TtEC entered into the settlement agreement and consent decree to avoid the delay, uncertainty and expense of protracted litigation. The settlement agreement and consent decree contain no admission of liability by TtEC. In addition, the settlement agreement and consent decree do not resolve the previously disclosed ancillary claims brought by third-party private plaintiffs from the same services provided by TtEC at Hunters Point.</p>
<p>&nbsp;</p>
<p>TtEC has initiated litigation with the insurance carrier with which TtEC maintained liability policies regarding the reasonably possible payment or reimbursement of a significant portion of the Settlement Amounts. TtEC can give no assurances as to what portion, if any, of the Settlement Amounts will be recovered from the insurance carrier.</p>


TTEK

Tetra Tech Subsidiary Settles Litigation for Hunters Point Remediation with U.S. For $97M; $57M For False Claims Act, $40M For Comprehensive Environmental Response, Compensation and Liability Act; Consent Decree Pending Public Comment And Court Approval; Settlement Agreement Involves No Admission Of Liability, Third-Party Claims Still Unresolved; Insurance Recovery Uncertain

<p>With <strong>Donald Trump</strong>&#8216;s swearing-in as the 47th president rapidly approaching, betting markets are in overdrive, pricing in a flurry of executive actions.</p>
<p>Traders on the CFTC-regulated platform <strong>Kalshi</strong> see an 80% chance Trump will sign at least 15 executive orders on his first day, with the most aggressive wagers banking on 50 or more — offering a 28% implied probability.</p>
<p>From a potential flood of executive orders to new tariffs, immigration crackdowns, and even Bitcoin policy shifts, the first days of the Trump administration could be some of the most consequential in recent history.</p>
<h1 class="wp-block-heading"><strong>How Many Executive Orders On Trump Day 1?</strong></h1>
<p>The Kalshi platform, which allows traders to bet on political and economic outcomes, indicates Trump will sign an average of 38 executive orders on Inauguration Day.</p>
<p><iframe loading="lazy" style="border: 0;" src="https://kalshi.com/external-widgets/events/KXEOCOUNTDAY1B-25JAN20?color_scheme=light&amp;widget_size=medium&amp;variant=a&amp;ids=KXEOCOUNTDAY1B-25JAN20-49&amp;ids=KXEOCOUNTDAY1B-25JAN20-22.0&amp;ids=KXEOCOUNTDAY1B-25JAN20-27.0" width="488px" height="196px"></iframe></p>

<p>For comparison, President Joe Biden issued 17 orders on his first day in 2021, while Trump signed 14 in 2017 during his first term. The most aggressive bet — on 50 or more orders — carries a 28% probability by Friday 3:10 p.m. ET, meaning a $1 wager could return $3 if Trump surpasses that threshold.</p>
<h1 class="wp-block-heading"><strong>Will Trump Lower Corporate And High-Earner Taxes?</strong></h1>
<p>Betting markets assign a 55% probability that Trump will cut corporate taxes this year, signaling a potential reversal of Biden-era policies. </p>
<p>Meanwhile, there&#8217;s an 89% chance that he will extend tax cuts for high earners, a key priority for his administration. Trump&#8217;s 2017 tax reform significantly reduced corporate tax rates from 35% to 21%. </p>
<h1 class="wp-block-heading"><strong>Immigration Crackdown: A Near Certainty</strong></h1>
<p>One of the most heavily priced-in actions is Trump&#8217;s potential move on illegal immigration. </p>
<p>Betting markets assign a 94% probability that he will take action on deportations within his first 100 days. </p>
<p>This aligns with his campaign rhetoric, where he vowed to reinstate and expand the &#8220;Remain in Mexico&#8221; policy, increase deportations, and impose tougher border controls.</p>
<h1 class="wp-block-heading"><strong>Tariffs: Who's In The Crosshairs?</strong></h1>
<p>Markets are also weighing in on which countries Trump may hit with tariffs in his first 48 hours.</p>
<ul>
<li><strong>China</strong>: 46% chance of new tariffs</li>
<li><strong>Mexico</strong>: 46% chance</li>
<li><strong>Canada</strong>: 35% chance</li>
<li><strong>European Union</strong>: 10% chance</li>
</ul>
<p><iframe loading="lazy" src="https://kalshi.com/external-widget/events-categorical/KXTARIFFSC-25JAN23?color_scheme=light&#038;widget_size=large" width="488px" height="242px" style="border:0" /></iframe></p>

<p>Trump has already promised to slap a 10% universal tariff on all imports and potentially much steeper duties on Chinese goods.</p>
<h1 class="wp-block-heading"><strong>Declaring A National Emergency: 80% Probability</strong></h1>
<p>Another major bet is whether Trump will declare a national emergency within his first 100 days — a scenario with an 80% probability.</p>
<p>While the specific trigger remains unclear, possibilities include immigration, trade or domestic unrest.</p>
<p>His 2019 national emergency declaration to fund the border wall set a precedent, making this a key market-moving event to watch.</p>
<h1 class="wp-block-heading"><strong>Bitcoin Reserve: A Surprising 66% Chance</strong></h1>
<p>A more unconventional wager is whether Trump will establish a National <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) Reserve this year, a market with a 66% implied probability.</p>
<p>While Trump was previously skeptical of cryptocurrencies, he recently shifted his stance, touting himself as a crypto-friendly candidate. </p>
<p>If he moves forward with such a reserve, it could mark a seismic shift in U.S. financial policy.</p>
<p><iframe loading="lazy" style="border: 0;" src="https://kalshi.com/external-widgets/events/KXBTCRESERVE-26?color_scheme=light&amp;widget_size=medium&amp;variant=a" width="488px" height="160px"></iframe></p>
<h1 class="wp-block-heading"><strong>Birthright Citizenship: A 69% Likelihood of Action</strong></h1>
<p>Markets are also pricing in a 69% chance that Trump will attempt to end birthright citizenship within his first 100 days. </p>
<p>This would likely face immediate legal challenges as the 14th Amendment guarantees citizenship to anyone born in the U.S. Nonetheless, it remains a high-priority issue for his administration and traders are betting on early executive action.</p>
<p><strong>Read Now:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43064144/wall-street-roars-ahead-of-trumps-inauguration-intel-rallies-bitcoin-tops-105000-whats-driving-markets-friday">Wall Street Roars Ahead Of Trump&#8217;s Inauguration, Intel Rallies, Bitcoin Tops $105,000: What&#8217;s Driving Markets Friday?</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Regulations

Econ #s

$BTC

Betting Markets Brace For Wave Of Executive Orders On Trump Day 1: Immigration, Tariffs Top Issues On The Table

NVDA

NVIDIA Says Implementation Of Additional Due Diligence Measures For Advanced Computing IC Rule Not Expected To Impact Ops/Sales To China; Co Is An Approved IC Designer

<p>Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) has been analyzed by 19 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $258.32, a high estimate of $310.00, and a low estimate of $210.00. Surpassing the previous average price target of $221.83, the current average has increased by 16.45%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737151256_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Royal Caribbean Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$295.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Jamie Rollo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$287.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$283.00</td>
<td>$257.00</td>
</tr>
<tr>
<td>Lizzie Dove</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Steven Wieczynski</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$310.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$272.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Richard Clarke</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$290.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$232.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$257.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$245.00</td>
<td>$244.00</td>
</tr>
<tr>
<td>Lizzie Dove</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$245.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Steven Wieczynski</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$243.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$244.00</td>
<td>$195.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Royal Caribbean Gr. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Royal Caribbean Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Royal Caribbean Gr's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RCL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Royal Caribbean Gr analyst ratings.</strong></a></p>
<h2>Get to Know Royal Caribbean Gr Better</h2>
<p>Royal Caribbean is the world's second-largest cruise company, operating 68 ships across five global and partner brands in the cruise vacation industry. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises. The selection of brands in the portfolio allows Royal to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in 2021.</p>
<h3>Royal Caribbean Gr: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Royal Caribbean Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>17.45%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Royal Caribbean Gr's net margin excels beyond industry benchmarks, reaching <strong>22.74%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Royal Caribbean Gr's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>17.02%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Royal Caribbean Gr's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.0%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>3.06</strong>, caution is advised due to increased financial risk.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Analyst Expectations For Royal Caribbean Gr's Future

<p>During the last three months, 4 analysts shared their evaluations of Reynolds Consumer Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REYN#NASDAQ">REYN</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $28.0, a high estimate of $29.00, and a low estimate of $27.00. A 4.27% drop is evident in the current average compared to the previous average price target of $29.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737151249_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Reynolds Consumer Prods among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Reynolds Consumer Prods. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Reynolds Consumer Prods compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Reynolds Consumer Prods's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Reynolds Consumer Prods's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/REYN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Reynolds Consumer Prods analyst ratings.</strong></a></p>
<h2>All You Need to Know About Reynolds Consumer Prods</h2>
<p>Reynolds Consumer Products Inc is a provider of household products. The firm is engaged in the production and sales of cooking products, waste and storage products, and tableware. It operates through four reportable segments namely, Reynolds Cooking and Baking, Hefty Waste and Storage, Hefty Tableware, and Presto Products. Reynolds Cooking and Baking segment produce branded and store brand aluminum foil, disposable aluminum pans, parchment paper, freezer paper, wax paper, butcher paper, plastic wrap, baking cups, oven bags and slow cooker liners.</p>
<h3>Breaking Down Reynolds Consumer Prods's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Reynolds Consumer Prods faced challenges, resulting in a decline of approximately <strong>-2.67%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Reynolds Consumer Prods's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>9.45%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Reynolds Consumer Prods's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>4.19%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Reynolds Consumer Prods's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.77%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.88</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


REYN

Demystifying Reynolds Consumer Prods: Insights From 4 Analyst Reviews

<p>During the last three months, 5 analysts shared their evaluations of Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Bank OZK, presenting an average target of $48.2, a high estimate of $53.00, and a low estimate of $40.00. This current average has increased by 3.88% from the previous average price target of $46.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737151237_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Bank OZK's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Olney</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$53.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$51.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Matt Olney</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bank OZK. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bank OZK compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Bank OZK's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Bank OZK's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OZK/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bank OZK analyst ratings.</strong></a></p>
<h2>Get to Know Bank OZK Better</h2>
<p>Bank OZK is a bank holding company that owns and operates a community bank, Bank of the Ozarks. The bank operates offices in Arkansas, Georgia, Florida, North Carolina, Texas, California, New York and Mississippi. It provides a range of banking services which include deposit services such as checking, savings, money market, time deposit and individual retirement accounts to loan services like real estate, consumer, commercial and industrial loans. Apart from providing traditional banking products and services it also provides treasury management, trust and wealth management, financial planning, online banking and other related services.</p>
<h3>Bank OZK: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Bank OZK's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>7.64%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Bank OZK's net margin is impressive, surpassing industry averages. With a net margin of <strong>41.88%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bank OZK's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.43%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Bank OZK's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.48%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Bank OZK's debt-to-equity ratio is below the industry average. With a ratio of <b>0.12</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 5 Analyst Projections For Bank OZK

<p>In the preceding three months, 4 analysts have released ratings for Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $233.75, along with a high estimate of $255.00 and a low estimate of $215.00. This upward trend is apparent, with the current average reflecting a 6.25% increase from the previous average price target of $220.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737151226_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Taiwan Semiconductor is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simon Coles</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Simon Coles</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Simon Coles</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Taiwan Semiconductor. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Taiwan Semiconductor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Taiwan Semiconductor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Taiwan Semiconductor's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TSM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Taiwan Semiconductor analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Taiwan Semiconductor</h2>
<p>Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with over 60% market share. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the us in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD, and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs. TSMC employs more than 73,000 people.</p>
<h3>Taiwan Semiconductor's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Taiwan Semiconductor showcased positive performance, achieving a revenue growth rate of <strong>38.95%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>42.81%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Taiwan Semiconductor's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.36%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Taiwan Semiconductor's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.35%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Taiwan Semiconductor's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.01</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 4 Analyst Projections For Taiwan Semiconductor

<p>15 analysts have expressed a variety of opinions on Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">12</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $20.53, along with a high estimate of $29.00 and a low estimate of $14.00. This current average has increased by 29.36% from the previous average price target of $15.87. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737151219_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Bitdeer Technologies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Lucas Pipes</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Darren Aftahi</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Darren Aftahi</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Mike Colonnese</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bitdeer Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bitdeer Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Bitdeer Technologies's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Bitdeer Technologies's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BTDR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bitdeer Technologies analyst ratings.</strong></a></p>
<h2>About Bitdeer Technologies</h2>
<p>Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway.</p>
<h3>Breaking Down Bitdeer Technologies's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Bitdeer Technologies's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-28.95%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Bitdeer Technologies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-80.76%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bitdeer Technologies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-10.02%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Bitdeer Technologies's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-5.35%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Bitdeer Technologies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.33</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BTDR

15 Analysts Assess Bitdeer Technologies: What You Need To Know

<p>Throughout the last three months, 5 analysts have evaluated KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated KORU Medical Systems and provided 12-month price targets. The average target is $4.7, accompanied by a high estimate of $6.00 and a low estimate of $3.50. Surpassing the previous average price target of $3.80, the current average has increased by 23.68%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737151209_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive KORU Medical Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chase Knickerbocker</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Frank Takkinen</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$5.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Chase Knickerbocker</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$5.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Caitlin Cronin</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$4.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$3.50</td>
<td>$3.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to KORU Medical Systems. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of KORU Medical Systems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for KORU Medical Systems's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into KORU Medical Systems's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/KRMD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on KORU Medical Systems analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About KORU Medical Systems</h2>
<p>KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).</p>
<h3>KORU Medical Systems's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> KORU Medical Systems displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>16.8%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> KORU Medical Systems's net margin excels beyond industry benchmarks, reaching <strong>-19.33%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> KORU Medical Systems's ROE excels beyond industry benchmarks, reaching <strong>-8.68%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> KORU Medical Systems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-5.78%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> KORU Medical Systems's debt-to-equity ratio is below the industry average at <strong>0.24</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


KRMD

Analyst Expectations For KORU Medical Systems's Future

<p>A benign December inflation report was all it took to ignite another strong rally on Wall Street, with major indices delivering their best weekly performance since the post-election <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43064144/wall-street-roars-ahead-of-trumps-inauguration-intel-rallies-bitcoin-tops-105000-whats-driving-markets-friday">surge in early November.</a></p>
<p>Heading into the week, markets were gripped by concerns over inflation and interest rates, pricing in just one rate cut by year-end while the 30-year Treasury <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42990155/5-yields-fuel-demand-treasury-etfs-despite-bond-market-pain-relief-rally">yield hovered around 5%.</a></p>
<p>Fresh data showed inflation rising for the third straight month up to 2.9%, yet right in line with forecasts. A softer core reading — excluding food and energy — gave traders hope that the Fed might cut rates at <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43003047/stocks-rise-on-core-inflation-slowdown-banks-rally-after-strong-q4-earnings-treasury-yields-plummet">least twice this year.</a></p>
<p>Adding fuel to the bull run, major banks kicked off the fourth-quarter 2024 earnings season with blowout results.</p>
<p>Financial stocks — as tracked by the <strong>Financials Select Sector SPDR Fund </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) — jumped 6% for the week, their best <a href="https://www.benzinga.com/news/earnings/25/01/43007354/big-banks-crush-q4-earnings-forecasts-financial-stocks-set-for-biggest-1-day-rally-since-trumps-election">rally since October 2023.</a> <strong>Goldman Sachs Group Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) led the charge among big players, surging 11% to hit record highs.</p>
<p>In commodities, oil briefly touched $80 per barrel before retreating after the approval of a ceasefire deal in Gaza <a href="https://www.benzinga.com/news/global/25/01/43055426/oil-dips-as-israeli-security-cabinet-approves-gaza-ceasefire-yet-experts-warn-red-sea-risks-persist">between Israel and Hamas.</a></p>
<p>In cryptocurrency markets, <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continues to defy gravity, surpassing $100,000, fueled by optimism over crypto-friendly policies under the incoming Donald Trump administration.</p>
<p>Trump will officially take office as the 47th U.S. president on Monday.</p>
<p><em>You might have missed&#8230;</em></p>
<h1 class="wp-block-heading"><strong>Bessent&#8217;s Economic Vision</strong></h1>
<p><strong>Scott Bessent</strong>, Trump's Treasury secretary nominee, laid out his economic agenda before the Senate, emphasizing tax cuts, deregulation, energy expansion and tougher trade policies — particularly targeting <a href="https://www.benzinga.com/government/regulations/25/01/43041207/5-things-investors-need-to-know-about-scott-bessents-economic-policies-as-he-faces-senate-grilling-for-treasury-job">China, Russia and Iran.</a></p>
<h1 class="wp-block-heading"><strong>Bitcoin Reserve Talks</strong></h1>
<p>Reports suggest Trump is open to the idea of a U.S. strategic Bitcoin reserve, a move that could reshape fiscal policy and <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43035888/donald-trump-reportedly-open-to-us-crypto-reserve-as-bitcoin-reserve-chatter-gathers-steam">spark industrywide debate.</a></p>
<h1 class="wp-block-heading"><strong>Detroit EV Surge</strong></h1>
<p><strong>Ford Motor Co.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) and <strong>General Motors Co.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) reported a sharp rise in electric vehicle sales, with the Mustang Mach-E and Cadillac Lyriq emerging <a href="https://www.benzinga.com/trading-ideas/25/01/42978236/us-electric-vehicle-sales-hit-record-1-3-million-units-in-2024-despite-tesla-declines-top-10-bestselling-models-list">as top sellers in 2024.</a></p>
<h1 class="wp-block-heading"><strong>TikTok Ban Upheld</strong></h1>
<p>The U.S. Supreme Court upheld a law forcing ByteDance to sell the TikTok app by Jan. 19 <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">over national security concerns.</a> Trump could attempt to roll back the <a href="https://www.benzinga.com/general/social-media/25/01/43018125/trump-considers-executive-order-to-save-tiktok-from-being-banned-in-4-days">ban after taking office.</a></p>
<p><strong>Read Now: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/01/43062563/imf-lifts-us-growth-outlook-betting-markets-raise-odds-on-trump-led-economic-boom">IMF Lifts US Growth Outlook, Betting Markets Raise Odds On Trump-Led Economic Boom</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Politics

Wall Street Rallies As Inflation Fears Recede, Banks Smash Earnings, Bitcoin Reclaims $100,000: This Week In The Markets

Incannex gets FDA okay for Phase 2 study of psilocybin drug

Incannex Healthcare GAAP EPS of -$1.15

Incannex Healthcare Limited Sponsored ADR ( ($IXHL) ) just unveiled an update. Incannex Healthcare Inc. has appointed Dr. Luigi M. Barbato as Chief...

Incannex Healthcare Appoints Dr. Barbato as CMO

Incannex Healthcare (IXHL) announced the appointment of Lou Barbato, M.D., as Chief Medical Officer, CMO, effective immediately. Dr. Barbato joins ...

Incannex appoints Barbato as Chief Medical Officer

16:22 EST Incannex (IXHL) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking ...

Incannex files $150M mixed securities shelf

16:15 EST Incannex (IXHL) files to sell 61.39M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, ma...

Incannex files to sell 61.39M shares of common stock for holders

Incannex Healthcare files $150M mixed securities shelf

RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up

Incannex Healthcare GAAP EPS of -$0.29 beats by $0.20

Incannex Healthcare Limited Sponsored ADR ( ($IXHL) ) has released its Q1 earnings. Here is a breakdown of the information Incannex Healthcare Limi...

Comments

Incannex Healthcare

Incannex Healthcare (IXHL) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga